

18 November 2016

Announcements

National Stock Exchange of Australia

PO Box 283

NEWCASTLE NSW 2300

Market Announcement – Glucose Biosensor Systems (Greater China)

iQX Ltd (NSX:IQX) Would like to announce the following planned tactics as part of the company's ongoing business strategy:

- Salivary Glucose Biosensor Commercialisation:
 - IPO of Glucose Biosensor Systems (Greater China) (GBSGC) on NASDAQ during the first half of 2017. GBSGC is a subsidiary of Life Science Biosensor Diagnostics, being a joint venture company co-owned with iQNovate Limited.
 - The objective of the listing, will be to fund the prelaunch and launch strategy of the Glucose Biosensor into the Greater China market. The blood glucose monitoring market in Greater China is estimated to be at US\$4b annually.
- IQX's planned cross listing on NASDAQ, is expected to follow the achievement of the above milestones.

Accordingly, IQX requests the removal of the previously requested trading halt.

For and on behalf of the Board.



G Incollingo
Company Secretary

SOURCE IQX Limited

iQX Ltd is a specialist life science investment and fund management organisation,

Sydney: 222 Clarence Street, Sydney, NSW 2000, Australia *Phone: +61 2 8239 5400 *Fax: +61 2 8362 9325

New York: 400 Madison Avenue, Suite 10A, New York City New York City NY10166 USA *Phone: +1 866 581 9127

London: 20 Broadwick Street, London, W1F-8HT, UK *Phone: +44 20 3356 4956

Shanghai: Level 31. Jin Mao Tower, 88 Shiji Avenue, Pudong, Shanghai, 200120, China *Phone: +86 21 2890 9033